Mutations in Ret in MEN 2

Part of the Medical Intelligence Unit book series (MIU.LANDES)


The different clinical varieties of MEN 2 (MEN 2A, MEN 2B, FMTC—see chapter 1) are associated with distinct types of mutation in the ret proto-oncogene. This genetic information coupled with a basic understanding of the ways in which the different types of mutation may affect the activity of the ret protein, has already provided interesting insights into the biology of receptor tyrosine kinases. A more detailed elucidation of the genotype: phenotype correlations in terms of different signaling pathways in different cell types provides a challenge for the future.


Multiple Endocrine Neoplasia Type Sporadic Medullary Thyroid Carcinoma Cytoplasmic Tyrosine Kinase Sporadic Pheochromocytoma Cysteine Codon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Iwamoto T, Taniguichi M, Asai N et al. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 1993; 8: 1087–91.PubMedGoogle Scholar
  2. 2.
    Schuchardt A, Srinivas S, Pachnis V, Constantini F. Isolation and characterization of a chicken homolog of the c-ret proto-oncogene. Oncogene 1994; 10: 641–49.Google Scholar
  3. 3.
    Sugaya R, Ishimara S, Hosoya T. A Drosophila homology of hu-man proto-oncogene ret transiently expressed in embyronic neuronal precursor cells including neuroblasts and CNS cells. Mechanisms of Development 1994; 45: 139–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Mulligan LM, Marsh DJ, Robinson BG et al. Genotype-phenotype correlation in MEN 2: Report of the International RET Mutation Consortium. J Intern Med 1995; 238: 343–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Mulligan LM, Eng C, Healey CS et al. Specific mutations of the ret proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994; 6: 70–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Gardner E, Mulligan LM, Eng C et al. Haplotype analysis of MEN 2 mutations. Hum Mol Genet 1994; 3: 1771–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Angrist M, Bolk S, Thiel B et al. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung’s disease. Hum Mol Genet 1995; 4: 821–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Attie T, Pelet A, Edery P et al. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 1995; 4: 1381–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Mulligan LM, Eng C, Attie T et al. Diverse phenotypes associated with exon 10 mutations in the RET proto-oncogene. Hum Mol Genet 1994; 3: 2163–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Borst MJ, Van Camp JM, Peacock ML, Decker RA. Mutation analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung’s disease. Surgery 1995; 117: 386–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Santoro M, Carlomagno F, Romano A et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995; 267: 381–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Borello MG, Smith DP, Pasini B et al. RET activation by germline MEN 2A and MEN 2B mutations. Oncogene 1995; 11: 2412–27.Google Scholar
  13. 13.
    Hofstra RMW, Landsvater RM, Ceccherini I et al. A mutation in the ret proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Carlson KM, Dou S, Chi D et al. Single missense mutation in the tyrosine kinase catalytic domain of the ret proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994; 91: 1579–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Eng C, Smith DP, Mulligan LM et al. Point mutation within the tyrosine kinase domain of the ret proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994; 3: 237–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Songyang Z, Carraway III KL, Eck MJ et al. Catalytic specificity of protein tyrosine kinases is critical for selective signalling. Nature 1995; 373: 536–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Eng C, Smith DP, Mulligan LM et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995; 10: 509–13.PubMedGoogle Scholar
  18. 18.
    Bolino A, Schuffenecker I, Luo Y et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995; 10: 2415–9.PubMedGoogle Scholar
  19. 19.
    Eng C, Mulligan LM, Smith DP et al. Mutations of the RET proto-oncogene in sporadic medullary thyroid carcinomas. Genes Chromosom Cancer 1995; 12: 209–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Zedenius J, Wallin G, Hamberger B et al. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by the screening of sporadic MTCs. Hum Mol Genet 1994; 3: 1259–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Blaugrund JE, Johns MMJ, Eby JY et al. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1995; 3: 1895–7.CrossRefGoogle Scholar
  22. 22.
    Lindor NM, Honchel R, Khosla S, Thibodeau SN. Mutations in the RET proto-oncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 1995; 80: 627–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Beldjord C, Desclaux-Arramond F, Raffin-Sanson M et al. The RET proto-oncogene in sporadic pheochromocytoma. Am J Hum Genet 1994; 55 (suppl): A51.Google Scholar
  24. 24.
    Santoro M, Rosati R, Grieco M et al. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990; 5: 1595–8.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

There are no affiliations available

Personalised recommendations